Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)

NCT02159573 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02159573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02159573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)
Lead sponsor
Biogen
Phase
Observational
Overall status
Completed
Start date
July 31, 2014
Completion date
January 31, 2015
Enrollment
530 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis